What is the recommended inpatient management for respiratory syncytial virus (RSV) infection?

RSV Inpatient Management

Inpatient management of RSV infection is primarily supportive care, focusing on hydration assessment, oxygen supplementation when SpO2 falls below 90%, and strict infection control measures—avoid routine use of bronchodilators, corticosteroids, ribavirin, chest physiotherapy, or antibiotics unless specific bacterial coinfection is documented. 1

Core Supportive Management

Hydration and Nutrition

• Assess hydration status and oral intake ability as a priority 1
• Provide feeding support (nasogastric or intravenous fluids) when oral intake is inadequate
• Monitor for signs of dehydration continuously

Oxygen Therapy

• Administer supplemental oxygen if SpO2 persistently falls below 90% in previously healthy infants 1
• Maintain SpO2 at or above 90% with adequate oxygen delivery
• Discontinue oxygen when SpO2 remains ≥90%, infant feeds well, and respiratory distress is minimal 1
• High-risk patients require close monitoring during oxygen weaning: premature infants and those with hemodynamically significant heart or lung disease 1
• Continuous SpO2 monitoring is not routinely needed as clinical course improves 1

Medications to AVOID Routinely

Bronchodilators

• Do not use routinely 1
• A carefully monitored trial of α-adrenergic or β-adrenergic medication is optional
• Continue only if documented positive clinical response using objective evaluation 1

Corticosteroids

• Should NOT be used routinely in bronchiolitis management 1

Ribavirin

• Should NOT be used routinely in children with bronchiolitis 1
• Exception: May consider aerosolized ribavirin (2g for 2h every 8h or 6g over 18h/day for 7-10 days) in immunocompromised patients (hematopoietic stem cell transplant recipients) with RSV lower respiratory tract disease 2
• Monitor for adverse effects: claustrophobia, bronchospasm, nausea, conjunctivitis, declining pulmonary function 2
• Apply precautions to avoid environmental exposure (teratogenic risk to pregnant healthcare workers) 2

Antibiotics

• Use only when specific bacterial coinfection is documented 1
• Treat bacterial infection as you would in absence of bronchiolitis 1

Chest Physiotherapy

• Should NOT be used routinely 1

Infection Control Measures (Critical Component)

Hand Hygiene (Most Important)

• Hand decontamination is the single most important step in preventing nosocomial RSV spread 1
• Decontaminate hands before and after direct patient contact, after touching objects near the patient, and after removing gloves 1
• Alcohol-based rubs are preferred over antimicrobial soap 1, 3
• Educate all personnel and family members on hand sanitation 1

Personal Protective Equipment

• Wear gloves when entering rooms of confirmed or suspected RSV patients or before handling respiratory secretions 4
• Change gloves between patients and decontaminate hands after removal 4
• Wear gown when soiling with respiratory secretions is anticipated (e.g., handling infants with RSV) 4
• Change gown after contact and before caring for another patient 4
• Wear surgical mask and eye protection when performing procedures generating respiratory secretion sprays 4

Patient Placement

• Place in private room when possible, or cohort with other RSV-positive patients without other infections 4
• Promptly perform rapid diagnostic testing to facilitate appropriate isolation precautions 4
• Limit patient movement/transport to essential purposes only 4

Staffing Restrictions

• Restrict healthcare personnel with acute upper respiratory symptoms from caring for high-risk infants (premature, immunocompromised, severe cardiopulmonary conditions, receiving chemotherapy) 4

Visitor Restrictions

• Do not allow persons with respiratory infection symptoms to visit pediatric, immunosuppressed, or cardiac patients 4

Special Populations

Premature Infants and High-Risk Children

• Close monitoring during oxygen weaning is mandatory 1
• Consider palivizumab prophylaxis for eligible patients (though this is prevention, not acute treatment) 1, 5

Immunocompromised Patients

• Consider combination therapy with aerosolized/systemic ribavirin plus IVIG for allogeneic HSCT patients with RSV lower respiratory tract disease 2
• Deferral of conditioning therapy should be considered for patients planned for allogeneic HSCT 2

Common Pitfalls to Avoid

1. Over-treatment with ineffective therapies: The evidence strongly recommends against routine bronchodilators, steroids, and ribavirin in immunocompetent children
2. Inadequate infection control: RSV survives on hard surfaces for ≥6 hours and spreads easily via contaminated hands 3
3. Premature oxygen discontinuation: Ensure infant is feeding well with minimal respiratory distress before stopping oxygen
4. Unnecessary antibiotics: Use only when bacterial coinfection is specifically documented
5. Neglecting hand hygiene: This remains the cornerstone of preventing nosocomial transmission